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Biogenesis of the platelet receptor for fibrinogen: Evidence for
separate precursors for glycoproteins HIb and IIIa
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ABSTRACT Congenital absence of platelet glycoproteins
fIb and Ila (GPIIb and GPHa) results in a severe bleeding
disorder characterized by defective platelet aggregation and
failure of fibrinogen to bind to platelets. GPIIb is a two-chain
protein containing disulfide-linked a and (3 subunits. GPIIb
and GPUIa are present as a heterodimeric, noncovalent
complex in the platelet plasma membrane and function as the
fibrinogen receptor. To characterize synthesis of these two
proteins, RNA isolated from a human leukemia cell line that
contains GPIIb and GPIia was translated in a wheat germ
cell-free system. Polyclonal antibodies specific for each protein
immunoprecipitated distinct [35SSmethionine-labeled precur-
sors, indicating that GPIIb and GPHIa are translated from
separate mRNAs. Moreover, using specific antibodies against
either intact unreduced GPIIb or the .8 subunit, we obtained
evidence for synthesis of a common polypeptide precursor for
GPIIba and GPilbp. Based on experiments using microsomal
membranes, it appears that GPIIb is integrated into the platelet
membrane with little or no cytoplasmic component. These
results suggest that precursors of GPIlb and GPia may be
encoded by separate genes and that each precursor is processed
before delivery to the plasma membrane.
Platelet aggregation at the site of vessel injury is a critical step
in the maintenance of normal hemostasis. Aggregation re-
quires the binding of fibrinogen to the surface of activated
platelets (1, 2). A large body of evidence now suggests that
two nonidentical platelet membrane glycoproteins, glycopro-
tein IIb (GPIIb) and glycoprotein IIIa (GPIIIa), mediate
aggregation by acting as receptors for fibrinogen (3-9). More
recent evidence suggests that they may also be receptors for
von Willebrand factor, fibronectin, and thrombospondin
(10-12). As determined by NaDodSO4/polyacrylamide gel
electrophoresis (PAGE), unreduced GPIIb has an apparent
Mr of 142,000 (13). Electrophoresis of the reduced protein
reveals that there are two disulfide-linked subunits: GPIIba
(Mr = 123,000) and GPIIb# (Mr = 22,000) (13). GPIIIa is a
single-chain glycoprotein. When electrophoresed in
NaDodSO4/polyacrylamide gels, reduction induces a shift in
apparent Mr from 88,000 to 105,000, presumably due to
unfolding of the molecule after cleavage of internal disulfide
bonds (13). GPIIb and GPIIIa are associated as a noncova-
lent, calcium-dependent heterodimer (GPIIb-IIIa) in Triton
X-100 solutions (14-16) and in the platelet membrane (6-9,
17).
The initial evidence for the role of the GPIIb-IIIa
heterodimer in platelet aggregation came from the studies of
patients with Glanzmann thrombasthenia, a hereditary bleed-
ing disorder in which platelets fail to aggregate or bind
fibrinogen in response to physiologic stimuli (18). The plate-
lets of these patients are deficient in GPIIb and GPIIIa,
presumably accounting for the functional defects (18-21).
The molecular basis for this unusual genetic abnormality, in
which two separate proteins are decreased in parallel, has not
yet been defined.
Because platelets are anucleate and make little or no
protein (22), study of the biosynthesis of GPIIb and GPIIIa,
and hence the molecular defect in Glanzmann thrombas-
thenia, has been limited. Human megakaryocytes, the bone
marrow cells from which platelets are derived, have been
difficult to purify in sufficient numbers to study protein
synthesis (23). Recently, a human erythroleukemia (HEL)
cell line has been described that contains several proteins
found in platelets and megakaryocytes, including GPIIb and
GPIIIa (24-26). We have used RNA from HEL cells to study
the synthesis and membrane insertion of GPIIb and GPIIIa in
a cell-free system. Our results suggest that GPIIb and GPIIIa
are translated from separate mRNAs. In addition, the a and
,3 subunits of GPIIb appear to be derived from a common
single-chain precursor. A preliminary report of this work has
been published in abstract form (27).
MATERIALS AND METHODS
Wheat Germ. Wheat germ extract was prepared according
to the method of Erickson and Blobel (28).
Membranes. Microsomal membranes were prepared from
freshly excised dog pancreas similar to the method of Walter
et al. (29) with the variation described previously (30).
Purification of GPIIb and GPIIla and Preparation of Anti-
bodies. The GPIIb-IIIa heterodimer was isolated from
Lubrol-PX-solubilized human platelet membranes by mono-
clonal antibody affinity chromatography (6). The individual
GPIIb and GPIIIa subunits were then separated by prepar-
ative NaDodSO4/PAGE under nonreducing conditions as
described (31, 32). Subunits were recovered electrophoreti-
cally (33). The same procedure was used for the isolation of
reduced subunits, except that GPIIb-IIIa was first reduced
and alkylated (34) and then applied to a discontinuous
preparative NaDodSO4/polyacrylamide gel. The purity of
the isolated subunits was confirmed by analytical
NaDodSO4/PAGE. Polyclonal antibodies were prepared by
injecting rabbits subcutaneously with 20-100 ,ug of purified
subunit emulsified in complete Freund's adjuvant. The rab-
bits were given booster injections subcutaneously twice at
2-week intervals with protein in incomplete adjuvant and then
bled 1 week after the second boost. Antibody titers as
assessed by immunoblotting ranged from 1:1000 to 1:5000.
Radiolabeling of Platelets. Platelets were surface labeled
with Nal25I by the lactoperoxidase method (35).
Cell Culture. HEL cells were grown as described (24).
Abbreviations: GPIIb, glycoprotein IIb; GPIIIa, glycoprotein Illa;
HEL, human erythroleukemia.
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Immunoblotting. Platelets and HEL cell membranes were
prepared as described (26). Proteins solubilized in 2%
NaDodSO4 were electrophoresed on a 7-15% polyacrylamide
gel (36) and then transferred to nitrocellulose (37, 38). Bound
antibody was then detected by an ELISA system
("Vectastain," Vector Laboratories, Burlingame, CA).
Cell-Free Translation. Total RNA was extracted from the
HEL cells by the guanidinium thioisocyanate method (39)
with a final phenol/chloroform extraction. RNA, at a con-
centration of 0.2 Ag/,dl of cell-free translation, was then
incubated with [35S]methionine in a wheat-germ translation
system for 90 min at 270C as described (40). In some
experiments translation mixtures were supplemented with
dog pancreatic microsomal membranes at a concentration of
3.75 A280 units/ml. After incubation of translation mixtures
for 90 min, phenylmethylsulfonyl fluoride was added to a
final concentration of 1 mM (except in proteolysis experi-
ments).
Posttranslational Proteolysis. After translation, aliquots
were adjusted to 10 mM CaCl2, and then trypsin was added
to a final concentration of 0.1 mg/ml. Digestion was carried
out for 1 hr at 220C. In some cases, detergent (final concen-
tration of 1% Triton X-100) was added before the digestion.
Proteolysis was terminated by the addition of phenylmeth-
ylsulfonyl fluoride and Trasylol (final concentration, 1 mM
and 0.1%, respectively).
Carbonate Extraction. Protein processing into microsomal
membranes was analyzed by treatment with Na2CO3 accord-
ing to the method of Fujiki et al. (41). The translation
products were treated with 100 mM Na2CO3 (pH 11.5) for 30
min on ice. The sample was then centrifuged at 200,000 x g
for 2 hr. The resulting supernatant or pellet was im-
munoprecipitated.
Immunoprecipitation. Aliquots of translation products
were diluted with Triton buffer (1% Triton X-100/100 mM
Tris HCl, pH 8.0/100 mM NaCl/10 mM EDTA). Two mi-
croliters of nonimmune or immune antiserum was added to
equal volumes of translated material, and samples were
incubated at 4°C for 12 hr. Protein A-Sepharose was added,
and samples were agitated at 4°C for 1 hr, then pelleted,
washed, and eluted (30). Samples were electrophoresed in
either NaDodSO4/7-15% gradient polyacrylamide or
NaDodSO4/7% polyacrylamide gels, and then fluorography
performed (42).
RESULTS
Characterization of Antisera. Immunoblotting was used to
characterize the specificities of the antibodies employed in
this study (Fig. 1). In Fig. LA, antiserum raised against
unreduced GPIIb reacted with a single protein of Mr =
142,000 in unreduced NaDodSO4/polyacrylamide gels of
HEL cell membrane and platelet proteins. When HEL cell
membrane and platelet proteins were reduced, the antiserum
reacted with two proteins in each preparation OfMr = 123,000
and 22,000, corresponding to the disulfide-bonded a and (3
subunits of GPIIb (13). In Fig. 1B, antiserum against the (3
chain of GPIIb was shown to react only with intact GPIIb in
nonreduced samples and the ,B subunit in reduced samples of
HEL cell membrane and platelet proteins. The anti-GPIIbs
antibody showed no detectable crossreactivity with GPIIba.
Two different antisera to GPIIIa were prepared (Fig. 1C).
Antiserum raised against nonreduced GPIIIa reacted strong-
ly with a HEL cell membrane protein (lane 1) and with
platelet GPIIIa (Mr = 90,000, lane 2). Antiserum raised
against reduced and alkylated GPIIIa (lanes 3 and 4) reacted
with a single protein ofMr = 105,000 in reduced gels ofHEL
cell membrane and platelet proteins, corresponding to re-
duced GPIIIa. Of note, antiserum to nonreduced GPIIIa
reacted poorly with the reduced protein, whereas antiserum
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FIG. 1. Specificity of antibodies against HEL cell and platelet
GPIIb, GPIlbs, and GPIIIa. After solubilization of HEL cell mem-
branes or platelets in 2% NaDodSO4 with or without reduction with
5% 2-mercaptoethanol, proteins were electrophoresed in a
NaDodSO4/exponential 7-15% polyacrylamide gel and then
electrophoretically transferred to nitrocellulose membranes. Strips
were then incubated with specific antisera (1:1000 dilution) for 1 hr.
Bound antibodies were detected by a commercial immunoperoxidase
technique (Vectastain). Lanes 1 and 3, 25 ,ug ofHEL cell membrane
proteins; lanes 2 and 4, 10 jig of total platelet proteins. (A) Anti-GPIIb
antisera. (B) Anti-GPIIbp antisera. (C) Antisera to nonreduced
GPIIa (lanes 1 and 2) or reduced and alkylated GPIIIa (lanes 3 and
4). NR, nonreduced; R, reduced. Molecular weights are shown as M,
x 10-3.
to reduced/alkylated GPIIIa reacted poorly with the
nonreduced protein (not shown).
When samples were electrophoresed under nonreducing
conditions in 7% polyacrylamide gels, HEL cell GPIIIa
migrated slightly slower than platelet GPIIIa (not shown).
The molecular basis for this difference remains to be deter-
mined. With this exception, our results confirm the molecular
and immunologic similarities of platelet and HEL cell GPIIb
and GPIIIa reported previously (26).
Immunoprecipitation of HEL Cell Proteins Synthesized in
Vitro. Fig. 2 demonstrates synthesis of 35S-labeled precursors
GPIlb













FIG. 2. Cell-free synthesis of GPIIb and GPIIIa using HEL cell
RNA. HEL cell RNA was translated in a wheat-germ system using
[35S]methionine. "S-labeled proteins were immunoprecipitated, re-
duced, and electrophoresed in NaDodSO4/polyacrylamide gels, and
fluorography was performed. Lanes 1-4 and 7-10 represent separate
100 Ad translation mixtures and immunoprecipitations with anti-
GPIIb and anti-GPIIIa, respectively. Lanes 1 and 7, samples of total
translation products. Lanes 5 and 6, '25I-surface-labeled platelets.
Lanes 2 and 8, nonimmune serum. Lane 3, anti-GPIIb antisera. Lane
4, same as lane 3 except that 10 ,ug of purified platelet GPIIba, was
added prior to the antiserum. Lane 9, antiserum against reduced and
alkylated GPIIIa. Lane 10, same as lane 9 except that 10 pg of
purified reduced and alkylated platelet GPIIIa was added prior to the
antiserum. In lanes 2, 3, 8, and 9, equal amounts of the buffer in
which the purified GPIIb and GPIIIa were suspended (lanes 4 and 10)
were added to the incubation mixture prior to immunoprecipitation.
Molecular weights are shown as M, x 10-3.
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of GPIIb and GPIIIa in a cell-free system using HEL cell
RNA. After translation, immunoprecipitates were reduced
and electrophbresed in NaDodSO4/polyacrylamide gels. An-
tiserum to GPIIb (lane 3) precipitated a protein larger in
molecular weight by -5000 than mature platelet '251-labeled
GPIIba (lane 5). To confirm that this translation product was
actually related to GPIIb, we used several controls. First,
nonimmune serum did not precipitate labeled proteins of
similar mobility (lane 2). Second, when purified unlabeled
platelet GPIIba was added to the translation mixture prior to
adding the anti-GPIIb antibody, the intensity of the labeled
immunoprecipitated protein was markedly diminished (lane
4). Thus, pure platelet GPIIba competed for the antibody with
the cell-free translation product, hereafter termed "pre-
GPIIb1." As an additional control (data not shown), when the
erythrocyte protein band 4.1 was added to the translation
mixture before adding the antibody, immunoprecipitation of
pre-GPIIb1 was not inhibited.
In our initial experiments we were unable to precipitate a
35s-labeled translation product with antibody to nonreduced
GPIIIa. We therefore prepared a polyclonal antibody to the
reduced and alkylated molecule. This antibody precipitated a
protein (lane 9) smaller in molecular weight by 10,000 than
mature platelet '251-labeled GPIIIa (lane 6). This band was not
seen with nonimmune serum (lane 8). In addition, this band
was not present when purified reduced and alkylated platelet
GPIIIa was added prior to adding the anti-GPIIIa antisera
(lane 10). Therefore, this translation product represents a
protein specifically related to GPIIIa, termed "pre-GPIIIa."
Bands other than pre-GPIIIa are seen in lane 9. Those that are
present in all three lanes (8-10), and hence do not undergo
competition by purified GPIIIa, represent nonspecific inter-
action of proteins with our polyclonal antibody. One minor
band of lower molecular weight than pre-GPIlb (Fig. 2, lane
3) and pre-GPIIIa (Fig. 2, lane 9) was seen. Since each of
these bands underwent competition by unlabeled purified
protein, they may represent incompletely translated pep-
tides.
Processing of GPIIb. Because the in vitro translated pro-
teins were of different molecular weights than mature
glycosylated platelet or HEL cell proteins, we next examined
the processing of pre-GPIIb1 in rough endoplasmic reticulum
using dog pancreatic microsomal membranes. Translations
were carried out in the presence or absence of membrane
vesicles. Fig. 3 shows the results of integration of pre-GPIIb1
within microsomal membranes. Lane 4 shows immuno-
precipitation of pre-GPIIb1 translated in the absence of
membranes. When treated with trypsin, the protein is digest-
ed, and the band disappears (lane 2). In lane 5 the results of
translation in the presence of membrane vesicles are seen.
After translation, vesicles were lysed and the translation
products were immunoprecipitated. A protein migrating
more slowly than pre-GPIIb1 was seen. This protein, termed
"pre-GPIIb2," was larger in molecular weight by -22,000
than mature, reduced platelet GPIIba (Mr = 123,000) shown
in lane 1. Since core glycosylation occurs in the rough
endoplasmic reticulum, the shift in molecular weight was
presumably due to insertion of the protein into the
microsomal membrane and addition of carbohydrate (43).
This interpretation was confirmed by treating immunopre-
cipitates of the pre-GPIIb2 precursor with endoglycosidase H
and observing that it migrated with pre-GPIIb1 (unpublished
data).
To further characterize membrane processing of translated
pre-GPIIbl, trypsin was added to the incubation mixture after
translation (lane 6). Proteins that were not integrated within
or translocated across the membrane vesicle would have
been accessible to digestion by trypsin. Since the pre-GPIIb2
band was intact, it represented proteins either integrated
within or translocated across the membrane and, hence,
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FIG. 3. Fluorograph demonstrating integration and processing of
GPIIb into microsomal membranes. HEL cell RNA was translated in
a wheat-germ system using [35S]methionine either in the presence or
absence of dog pancreatic microsomal membranes. Aliquots were
then treated with trypsin or buffer, immunoprecipitated, and elec-
trophoresed, and fluorography was performed. Lane 1, 125I-surface-
labeled platelets. Lanes 2-6, immunoprecipitates of 35S-labeled
translation products electrophoresed in a 7% polyacrylamide gel.
Translations were carried out in the presence (lanes 5 and 6) or
absence (lanes 2-4) ofdog pancreatic microsomal membranes. Lanes
2 and 4-6, anti-GPIIb antisera. Lane 3, nonimmune serum. Lanes 2
and 6 represent the results of posttranslational proteolysis. Trypsin
was incubated with translation products at a concentration of 0.1
mg/ml, for 1 hr at 220C, prior to immunoprecipitation. Molecular
weights are shown as Mr x 10-3.
protected from digestion by trypsin. Pre-GPIIbl, which
represented proteins not inserted into membranes and there-
fore not protected from digestion by trypsin, was not seen.
When detergent (1% Triton X-100) was added to the incuba-
tion mixture with trypsin, no bands were immunoprecipitated
(data not shown), indicating that an intact membrane vesicle
is necessary to prevent digestion of pre-GPIIb2.
PreGPIb2 Is Integrated Within the Microsomal Membrane.
Since pre-GPIIb2 did not shift in molecular weight after
treatment with trypsin, it could represent either an integral
membrane protein with little or no cytoplasmic component or
a secretory protein completely translocated across the mem-
brane. Fig. 4 shows the results of carbonate extraction of
GPIIb integrated within microsomal membranes. Proteins
were translated in the presence of membranes, which were
then treated with Na2CO3 (pH 11.5) and centrifuged, and the
resulting supernatant (lane 1) and pellet (lane 2) were im-
munoprecipitated. Carbonate extraction converts membrane
vesicles into sheets, releasing secretory proteins, leaving
only those proteins integrated into the bilayer to sediment
with the membrane remnants (41). The pre-GPIIb2 band was
localized entirely to the pelleted membrane fraction, indicat-





FIG. 4. Carbonate extraction of GPIIb
integrated within microsomal membranes.
pre-CPIIbp Cell-free synthesis of 35S-labeled proteinsin the presence of microsomal membranes
was followed by treatment with 100 mM
Na2CO3 for 30 min at 0-40C. The sample
was centrifuged at 200,000 x g for 2 hr.
Lane 1, immunoprecipitation of the super-
natant with anti-GPIIb antisera. Lane 2,
immunoprecipitation of the solubilized
pellet. Molecular weights are shown as M,
X 10-3.
Proc. Natl. Acad. Sci. USA 83 (1986)







FIG. 5. Immunoprecipitation of HEL cell translation products
with anti-GPIIb and anti-GPIIbs antisera. Translations were per-
formed in the presence (lanes 4 and 5) or absence (lanes 3 and 6) of
microsomal membranes. A fluorograph of a NaDodSO4/7-15%
polyacrylamide gel is shown. Lane 1, 12I-labeled platelets. Lane 2,
nonimmune serum. Lanes 3 and 4, anti-GPIIb antisera. Lanes S and
6, anti-GPIIbs antisera. Molecular weights are shown as Mr x 10-.
pre-GPIIb1 protein was shown to distribute between the
supernatant (lane 1) and pellet (lower band, lane 2) fractions
in a fashion characteristic of a nonintregrated membrane
protein (unpublished observation).
Synthesis of a Common Precursor of the a and Subunits
of GPIIb. Further processing ofthe glycosylated precursor of
GPIIb must occur since in reduced gels it is larger in
molecular weight by -20,000 than mature GPIIb,. This
difference is approximately equal to the molecular weight of
the subunit of GPIIb. The possibility that the a and
subunits of GPIIb are derived from a single precursor was
explored by immunoprecipitating translation products with a
polyclonal antibody that recognizes the a but not the a









FIG. 6. Effect of purified unlabeled GPIIbh and GPIIbq on
immunoprecipitation of cell-free synthesized proteins with anti-
GPIIb,. Prior to immunoprecipitation of translated proteins, either
purified unlabeled platelet protein or the buffer in which the proteins
were suspended was added to the samples. A fluorograph of a
NaDodSO4/7-15% polyacrylamide gel is shown. Lane 1, III-labeled
platelets. Immunoprecipitates of translation products are represent-
ed in lanes 2-5. Lane 2, nonimmune serum. Lanes 3-5, anti-GPIIbs
antisera. Platelet GPIIbs (lane 4, 1 s.g), platelet GPIIbe (lane 5,5 ,ug),
and the buffer in which the purified proteins were suspended (lane 3)
were added to 50 ul of the mixture of synthesized proteins prior to
immunoprecipitation. Molecular weights are shown as M, x 10-3.
subunit. In Fig. 5, antisera against GPIIbp (lanes 5 and 6) andintact GPIIb (lanes 3 and 4) immunoprecipitated 3"S-labeled
proteins with the same mobilities of pre-GPIIb1 and pre-
GPIIb2 in the NaDodSO4/polyacrylamide gel. This fluoro-
gram has more nonspecific bands because it was exposed
longer in an attempt to identify mature GPIIb1, which would
presumably have had fewer [35S]methionine molecules in-
corporated. To confirm that the precursor precipitated by
anti-GPIIbs contains the 3 subunit, competition experiments
with unlabeled purified platelet GPIIb, or GPIIb,9 were
performed (Fig. 6). Immunoprecipitation of 3"S-labeled pre-
GPIIb1 is seen in lane 3. Purified platelet GPIIbp inhibitsimmunoprecipitation ofpre-GPIIb1 (lane 4), whereas purified
platelet GPIIba does not (lane 5). These results indicate that
GPIIb is synthesized as a single high molecular weight
polypeptide containing the a and A3 subunits.
Despite use of antibodies to the unreduced and reduced/
alkylated protein, we have been unable to demonstrate
incorporation of GPIIIa into membrane vesicles. The exper-
imental conditions required to demonstrate incorporation of
GPIIIa into membranes in the in vitro system remain to be
determined.
DISCUSSION
We have described the in vitro synthesis of separate precur-
sors for GPIIb and GPIIIa. Since immunoprecipitations were
performed in the presence ofprotease inhibitors, it is unlikely
that GPIIb and GPIIIa are proteolytic cleavage products of a
common polypeptide precursor. Furthermore, we have im-
munoprecipitated separate "S-labeled precursors synthe-
sized by intact cultured HEL cells (unpublished data). Our
findings therefore suggest that GPIIb and GPIIIa are trans-
lated from separate mRNAs. The simplest interpretation of
the data is that GPIIb and GPIIIa are encoded by separate
genes that transcribe separate mRNAs. Alternatively, a
single gene might transcribe a precursor mRNA that is
processed into separate mRNAs for GPIIb and GPIIIa.
Alternative mRNA splicing has been described for a number
of proteins, including fibronectin (44), and the y chain of
fibrinogen (45). In each case, the alternatively translated
polypeptides share substantial N-terminal amino acid se-
quence and immunologic crossreactivity. Since GPIIb and
GPIIIa are immunologically distinct and have dissimilar
tryptic peptide maps (31, 46), it is unlikely that they are
synthesized in this manner. However, direct analysis ofRNA
with DNA probes will be required to definitively exclude a
common mRNA for GPIIb and GPIIIa.
Immunoprecipitation of pre-GPIIb1 with anti-GPIIbp anti-body suggests that the a and (B subunits of GPIIb are
synthesized as a common precursor. The observation that
purified GPIIba does not inhibit precipitation of pre-GPIIb1
by anti-GPIIbs implies that there are no significant antigenic
similarities in the a and ( subunits and that immunoprecip-
itation of the precursor for GPIIb by anti-GPIIbs is not due
to crossreactivity of the a and ,3 subunits with the antibody.
This is consistent with the lack of detectable crossreactivity
of the antibodies on immunoblots and strengthens our con-
clusion that there is a common precursor for GPIIbaX and
GPIIb9. In vivo, this common precursor, pre-GPIIb2, must
undergo proteolytic cleavage, resulting in formation of a
two-chain molecule with the a and 6 subunits seen in mature
platelet and HEL cell GPIIb. GPIIb is thus analogous to
several other molecules consisting of two or more disulfide-
linked chains, such as the secretory component of glandular
epithelial cells (47) and the insulin receptor (48), which are
derived from single-chain precursors.
We have also demonstrated membrane insertion and
glycosylation of GPIIb in vitro. This system lacks the ability
to add complex carbohydrate chains and apparently lacks the
enzyme responsible for subunit cleavage. The observation
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that pre-GPIIb2 incorporated into microsomal membranes
did not change in molecular weight after treatment with
trypsin suggests the lack of an available trypsin cleavage site
on the cytoplasmic domain of this integral membrane protein.
Since GPIIb contains numerous trypsin-sensitive sites (31,
46), this indicates that it has little or no cytoplasmic compo-
nent. Parise and Phillips recently demonstrated incorporation
of purified GPIIb-IIIa into phospholipid vesicles (49). Elec-
tron micrographs of the incorporated heterodimer suggested
that GPIIb attached indirectly to the membrane by the GPIIIa
"tail," although GPIIb remained attached to vesicles after
dissociation of the GPIIb-IIIa complex with EDTA. Our
findings support the conclusion that the bulk of GPIIb is
oriented external to the membrane but also indicate that it is
stably incorporated into the membrane.
The explanation for our inability to demonstrate incorpo-
ration of GPIIIa into membrane vesicles is unclear. The
conditions used for cell-free synthesis may have lacked a
critical component necessary for insertion of GPIIIa into the
membrane. In preliminary experiments, we have demonstrat-
ed synthesis of GPIIIa in intact [3H]mannose-labeled HEL
cells (unpublished data). Thus, GPIIIa as well as GPIIb are
translocated in vivo across the endoplasmic reticulum where
initial glycosylation and processing occur. Presumably the
two molecules are assembled as heterodimers after entering
the endoplasmic reticulum while en route to the plasma
membrane.
Study of the synthesis of platelet and megakaryocyte
proteins has been difficult because megakaryocytes repre-
sent only about 0.05% of the cells in the bone marrow and are
therefore difficult to analyze in large numbers or high degrees
of purity (23). We have demonstrated the ability to use a
continuous cell line with megakaryocytic properties for
studies of synthesis ofplatelet proteins. HEL cells may prove
useful in studies of other platelet proteins in the future.
It remains to be determined why GPIIb and GPIIIa are
absent or decreased in parallel in platelets from patients with
Glanzmann thrombasthenia. If separate genes encode each
protein, it is possible that transcription ofboth is coordinately
regulated. If so, a defect in a regulatory element could affect
the transcription of both genes. Alternatively, a molecular
defect resulting in deficiency of either GPIIb or GPIIIa could
result in instability or improper processing of the other
protein. For example, transport of both proteins to the cell
surface may require a sorting signal from one protein for
transport of the other, as is the case with the HLA heavy
chain and (32-microglobulin (50, 51). Detailed studies of the
genetic regulation of synthesis of GPIIb and GPIIIa should
provide insight into these issues.
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